Physicochemical Properties
| Molecular Formula | C20H13F9N2O3 |
| Molecular Weight | 500.3145 |
| Exact Mass | 500.078 |
| CAS # | 1928724-23-5 |
| PubChem CID | 127043517 |
| Appearance | White to off-white solid powder |
| LogP | 4.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 34 |
| Complexity | 752 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | FC(C1C([H])=C(C(F)(F)F)C([H])=C(C=1[H])OC([H])([H])C(C([H])([H])[H])(C(N([H])C1C([H])=C([H])C(C#N)=C(C(F)(F)F)C=1[H])=O)O[H])(F)F |
| InChi Key | VJIVKRQGSGBLFP-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C20H13F9N2O3/c1-17(33,16(32)31-13-3-2-10(8-30)15(7-13)20(27,28)29)9-34-14-5-11(18(21,22)23)4-12(6-14)19(24,25)26/h2-7,33H,9H2,1H3,(H,31,32) |
| Chemical Name | 3-[3,5-bis(trifluoromethyl)phenoxy]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide |
| Synonyms | SK 33; SK-33 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | SK33 exhibited notable and strong action in LNCaPAR+ cells, with an IC50 of 0.2 μM. LNCaP cell progression into the S phase is inhibited by SK33. SK33 treatment of LNCaP/BicR cells for 96 hours at increasing doses resulted in a dose-dependent response and a growth inhibition of the cells with an IC50 of about 5 μM [1]. |
| ln Vivo | SK33 suppresses the transcriptional activity of AR (50 mg/kg; subcutaneous injection; 24 hours) [1]. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: LNCaP/BicR Cell Tested Concentrations: 0.1-100 μM Incubation Duration: 96 hrs (hours) Experimental Results: Produce a dose-dependent response and inhibit cell growth. |
| Animal Protocol |
Animal/Disease Models: ARE-Luc mice [1] Doses: 50 mg/kg Route of Administration: subcutaneous injection; 24-hour Experimental Results: AR transcription activity was inhibited. |
| References |
[1]. Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo.Mol Cancer Ther. 2018 Sep;17(9):1846-1858. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~199.88 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9988 mL | 9.9938 mL | 19.9876 mL | |
| 5 mM | 0.3998 mL | 1.9988 mL | 3.9975 mL | |
| 10 mM | 0.1999 mL | 0.9994 mL | 1.9988 mL |